Breast cancer
CDK4/6 inhibitors for everyone? Treatment strategies in HR+ HER2- advanced breast cancerJohanna (72 years old)
Johanna, 72 years old, was diagnosed with metastatic breast cancer 1 year ago, after she had been treated for early HR+ HER2- breast cancer 8 years ago.
Assessment summary:
- Postmenopausal
- Medical history:
- HR+ HER2- breast cancer T2N0M0 8 years ago. Treated with breast conserving surgery, radiation therapy and letrozole for 5 years
- Diagnosis metastatic disease 1 year ago (bones, liver). Biopsy of liver metastasis: breast cancer, NST, ER 90%, PgR 60%, HER2 IHC 1+, G2. Endocrine monotherapy with anastrozole was started
- Tumour regression in control imaging
- ECOG PS: 0
- No family history of breast cancer
- Most recent CT scan of chest and abdomen and bone scan:
- Stable multiple bone metastases
- Progression of 2 liver metastases
- Haematology and biochemistry: all values normal
- Germline BRCA-status: wild type
- PIK3CA-status in the tumour: wild type